BioCryst Pharmaceuticals, Inc. (BCRX) vs Supernus Pharmaceuticals, Inc. (SUPN)
- BioCryst Pharmaceuticals, Inc. BCRX 7.79 −2.87%
- Supernus Pharmaceuticals, Inc. SUPN 37.88 −4.27%
BioCryst Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Supernus Pharmaceuticals, Inc. is the larger, with a market value of $2.3B against $2.1B — 1.1× the size. BioCryst Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 68.7% against 24.9%. Supernus Pharmaceuticals, Inc. has the higher net margin (−13.2% vs −40.9%) and the higher return on invested capital (−12.4% vs −610.6%). Across the 18 metrics below, BioCryst Pharmaceuticals, Inc. leads on 12 and Supernus Pharmaceuticals, Inc. on 6.
Valuation
Profitability
| Metric | BCRX | SUPN | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.78% | 88.07% | 53.94% |
| Operating margin | (33.29%) | (15.71%) | 0.00% |
| Net margin | (40.90%) | (13.23%) | 0.00% |
| Free cash flow margin | 39.75% | 2.21% | 0.00% |
| Return on equity | 87.84% | (10.49%) | (0.40%) |
| Return on assets | (75.79%) | (7.82%) | (3.32%) |
| Return on invested capital | (610.55%) | (12.37%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack